LENZ Therapeutics, Inc.
General ticker "LENZ" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $722.0M (TTM average)
LENZ Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -28.0%.
Estimated limits based on current volatility of 4.2%: low 5.51$, high 5.98$
Factors to consider:
- Total employees count: 69 as of 2021
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Dependence on single product candidate, Lack of market acceptance, Regulatory and compliance, Market competition, Third-party risks
- Current price 44.0% below estimated low
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [9.47$, 22.21$]
- 2026-12-31 to 2027-12-31 estimated range: [7.38$, 17.47$]
Financial Metrics affecting the LENZ estimates:
- Negative: with PPE of -6.0 at the end of fiscal year the price was high
- Negative: Operating cash flow per share per price, % of -14.34 <= 0.30
- Negative: negative Operating income
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
Short-term LENZ quotes
Long-term LENZ plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $19.09MM |
| Operating Expenses | $135.19MM | $58.61MM | $110.23MM |
| Operating Income | $-135.19MM | $-58.61MM | $-91.14MM |
| Non-Operating Income | $10.54MM | $8.84MM | $9.51MM |
| R&D Expense | $32.14MM | $29.80MM | $18.67MM |
| Income(Loss) | $-124.65MM | $-49.77MM | $-81.62MM |
| Taxes | $0.00MM | $0.00MM | $0.50MM |
| Net Income(Loss)* | $-124.65MM | $-49.77MM | $-82.13MM |
| Stockholders Equity | $183.58MM | $204.08MM | $284.34MM |
| Assets | $188.46MM | $215.30MM | $305.88MM |
| Operating Cash Flow | $-60.38MM | $-59.39MM | $-69.17MM |
| Capital expenditure | $0.03MM | $0.47MM | $0.83MM |
| Investing Cash Flow | $-29.62MM | $-154.48MM | $-75.67MM |
| Financing Cash Flow | $80.70MM | $199.00MM | $149.75MM |
| Earnings Per Share** | $-15.30 | $-2.34 | $-2.85 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.